- Home
- PAMT vs TNYA Comparison
PAMT vs TNYA Comparison
Compare PAMT & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
Current Price
$11.38
HOLD
Current Price
$0.80
Company Overview
Basic Information| Metric | PAMT | TNYA |
|---|---|---|
| Founded | 1980 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trucking Freight/Courier Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.0M | 234.8M |
| IPO Year | 1985 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PAMT | TNYA |
|---|---|---|
| Price | $11.38 | $0.80 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | ★ $13.00 | $7.80 |
| AVG Volume (30 Days) | 30.3K | ★ 7.8M |
| Earning Date | 02-10-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $623,270,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.19 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.90 | $0.36 |
| 52 Week High | $17.39 | $2.35 |
Technical Indicators
Market Signals| Indicator | PAMT | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 52.85 | 40.54 |
| Support Level | $11.76 | $0.72 |
| Resistance Level | $12.49 | $0.76 |
| Average True Range (ATR) | 0.79 | 0.06 |
| MACD | -0.03 | 0.02 |
| Stochastic Oscillator | 41.60 | 85.39 |
Price Performance
Historical Comparison PAMT
TNYA
About PAMT PAMT CORP
PAMT Corp is a holding company that is engaged in providing truckload dry van carriers transporting general commodities throughout the continental United States, as well as the Canadian provinces of Ontario and Quebec. It has one reportable segment being motor carrier.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.